INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,886,239 | +0.6% | 29,789 | -9.3% | 0.35% | -23.8% |
| Q2 2022 | $1,875,000 | -24.0% | 32,849 | -18.5% | 0.46% | -0.4% |
| Q1 2022 | $2,468,000 | +11.2% | 40,330 | -4.9% | 0.46% | +26.4% |
| Q4 2021 | $2,219,000 | +12.8% | 42,404 | -12.1% | 0.36% | +19.7% |
| Q2 2021 | $1,968,000 | +98.8% | 48,220 | +24.9% | 0.30% | +29.4% |
| Q3 2020 | $990,000 | +23.0% | 38,600 | +86.1% | 0.24% | +94.2% |
| Q2 2016 | $805,000 | -5.4% | 20,737 | -32.2% | 0.12% | -9.0% |
| Q1 2016 | $851,000 | -85.1% | 30,598 | -71.2% | 0.13% | -82.2% |
| Q4 2015 | $5,715,000 | +50.0% | 106,243 | +11.6% | 0.75% | +23.9% |
| Q3 2015 | $3,811,000 | -21.7% | 95,168 | -37.5% | 0.60% | +5.8% |
| Q2 2015 | $4,869,000 | +341.8% | 152,389 | +230.3% | 0.57% | +348.8% |
| Q1 2015 | $1,102,000 | – | 46,132 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |